StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
19
Publishing Date
2024 - 04 - 24
11
2024 - 04 - 02
9
2024 - 03 - 05
9
2023 - 12 - 20
10
2023 - 12 - 18
11
2023 - 12 - 13
9
2023 - 12 - 12
13
2023 - 12 - 11
16
2023 - 11 - 06
9
2023 - 11 - 03
10
2023 - 11 - 02
10
2023 - 10 - 16
11
2023 - 09 - 26
12
2023 - 09 - 18
9
2023 - 09 - 11
9
2023 - 07 - 17
14
2023 - 06 - 05
13
2023 - 05 - 25
11
2023 - 05 - 16
11
2023 - 05 - 09
10
2023 - 04 - 26
10
2023 - 04 - 17
9
2023 - 03 - 29
9
2023 - 03 - 06
11
2023 - 02 - 16
10
2022 - 11 - 03
10
2022 - 09 - 26
10
2022 - 09 - 16
9
2022 - 06 - 22
9
2022 - 06 - 10
9
2022 - 05 - 19
8
2022 - 04 - 25
8
2022 - 02 - 25
9
2022 - 02 - 14
9
2021 - 12 - 13
19
2021 - 12 - 09
16
2021 - 12 - 06
8
2021 - 11 - 30
8
2021 - 11 - 29
12
2021 - 11 - 15
9
2021 - 11 - 12
12
2021 - 11 - 08
8
2021 - 10 - 25
8
2021 - 10 - 15
9
2021 - 10 - 07
8
2021 - 10 - 04
9
2021 - 09 - 27
11
2021 - 09 - 20
13
2021 - 09 - 17
11
2021 - 09 - 16
9
2021 - 09 - 13
12
2021 - 09 - 08
8
2021 - 06 - 29
8
2021 - 06 - 28
8
2021 - 06 - 25
10
2021 - 06 - 11
9
2021 - 06 - 07
8
2021 - 05 - 21
15
2021 - 05 - 20
8
2021 - 03 - 24
8
Sector
Health technology
16
Manufacturing
2
Non-energy minerals
1
Tags
613
1
Allo-715
1
Als
3
Anemia
1
Atopic dermatitis
1
Bioscience
2
Biotech-bay
1
Biotech-beach
2
Biotechnology
2
Blu-5937
1
Cancer
1
Cel
1
Children
1
Chronic cough
1
Cirrhosis
1
Clinical-trials-phase-ii
3
Clinical-trials-phase-iii
1
Comp360
1
Depression
1
Dermatitis
1
Designation
1
Disease
2
Dp0004
1
Dupixent
1
Ema
4
Europe
1
Events
1
Fda
1
Ft516
1
Ft596
1
Galectin-3
1
Gb1211
1
Gbt0216
1
Gene therapies
1
Gene therapy
1
Genetown
1
Gment-101
1
Granted
1
Health
2
Hoice-01
2
Liver
1
Liver cirrhosis
1
Lung cancer
1
N/a
4
Phase 1
8
Phase 1b
2
Phase 2
1
Phase 2b
3
Phase 3
2
Positive
19
Positive results
2
Research
2
Results
8
T-cell
3
Therapeutics
7
Therapy
4
Topline
2
Topline results
2
Treatment
5
Trial
6
Entities
4d pharma plc - adr
1
Abbvie inc.
2
Allogene therapeutics, inc.
2
Autolus therapeutics plc
1
Bellus health inc.
1
Coherus biosciences, inc.
2
Compass pathways plc
1
Equillium, inc.
1
Fate therapeutics, inc.
2
Galecto, inc.
1
Global blood therapeutics, inc.
1
Kymera therapeutics, inc.
1
Regeneron pharmaceuticals, inc.
1
Rocket pharmaceuticals, inc.
1
Sanofi
1
Ssr mining inc.
1
Syndax pharmaceuticals, inc.
1
Teva pharmaceutical industries ltd
1
Viracta therapeutics inc
1
Symbols
ABBV
2
ALLO
2
AUTL
1
BLU
1
CHRS
2
CMPS
1
EQ
1
FATE
2
GBT
1
GLTO
1
KYMR
1
LBPS
1
RCKT
1
REGN
1
SNDX
1
SNY
1
SNYNF
1
SSRM
1
TEVJF
1
VIRX
1
Exchanges
Nasdaq
19
Nyse
2
Crawled Date
2021 - 12 - 13
19
Crawled Time
08:00
2
12:30
1
13:30
1
14:00
1
14:30
1
15:00
2
15:30
1
18:00
2
20:00
3
21:00
1
22:00
2
23:00
2
Source
www.4dpharmaplc.com
1
www.biospace.com
15
www.globenewswire.com
1
www.prnewswire.com
2
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
positive
publishing date :
2021 - 12 - 13
save search
Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613
Published:
2021-12-13
(Crawled : 23:00)
- biospace.com/
SNDX
|
$20.82
-0.72%
62K
|
Health Technology
|
19.15%
|
O:
-6.48%
H:
18.59%
C:
10.02%
gment-101
als
613
trial
phase 1
positive
SSR Mining Announces Positive Exploration Results at the Amisk Gold Property in Saskatchewan
Published:
2021-12-13
(Crawled : 23:00)
- prnewswire.com
SSRM
|
$5.39
3.45%
720K
|
Non-Energy Minerals
|
-68.96%
|
O:
-2.6%
H:
1.67%
C:
-0.3%
positive
results
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
Published:
2021-12-13
(Crawled : 22:00)
- biospace.com/
CMPS
|
$8.2
-0.61%
160K
|
Health Technology
|
-68.74%
|
O:
-5.04%
H:
0.0%
C:
0.0%
comp360
treatment
positive
therapy
depression
psilocybin
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
Published:
2021-12-13
(Crawled : 22:00)
- biospace.com/
FATE
|
News
|
$4.38
-3.52%
530K
|
Health Technology
|
-90.76%
|
O:
-0.1%
H:
0.0%
C:
0.0%
ft596
therapeutics
phase 1
positive
t-cell
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published:
2021-12-13
(Crawled : 21:00)
- globenewswire.com
ABBV
|
News
|
$168.1
-0.85%
670K
|
Health Technology
|
36.86%
|
O:
1.07%
H:
0.0%
C:
0.0%
CHRS
|
$2.11
-3.21%
190K
|
Health Technology
|
-87.03%
|
O:
-0.83%
H:
0.0%
C:
0.0%
hoice-01
treatment
trial
lung cancer
positive
therapy
bioscience
results
cancer
phase 3
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
Published:
2021-12-13
(Crawled : 20:00)
- biospace.com/
ALLO
|
$3.175
-5.79%
270K
|
Health Technology
|
-81.31%
|
O:
1.05%
H:
2.52%
C:
-22.56%
allo-715
ema
therapeutics
positive results
phase 1
positive
therapy
results
t-cell
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
Published:
2021-12-13
(Crawled : 20:00)
- biospace.com/
ALLO
|
$3.175
-5.79%
270K
|
Health Technology
|
-81.31%
|
O:
1.05%
H:
2.52%
C:
-22.56%
ema
als
trials
trial
therapeutics
phase 1
positive
Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021
Published:
2021-12-13
(Crawled : 20:00)
- biospace.com/
VIRX
|
$0.869
2.5%
34K
|
Manufacturing
|
-79.76%
|
O:
-2.86%
H:
0.0%
C:
0.0%
phase 1b
therapeutics
presentation
phase 1
positive
phase 2b
Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition
Published:
2021-12-13
(Crawled : 18:00)
- biospace.com/
AUTL
|
$4.405
-1.67%
720K
|
Health Technology
|
-34.79%
|
O:
-3.93%
H:
0.0%
C:
0.0%
therapeutics
positive
cel
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01
Published:
2021-12-13
(Crawled : 18:00)
- biospace.com/
ABBV
|
News
|
$168.1
-0.85%
670K
|
Health Technology
|
36.86%
|
O:
1.07%
H:
0.0%
C:
0.0%
CHRS
|
$2.11
-3.21%
190K
|
Health Technology
|
-87.03%
|
O:
-0.83%
H:
0.0%
C:
0.0%
hoice-01
positive
bioscience
results
GBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers at ASH Annual Meeting and Exposition
Published:
2021-12-13
(Crawled : 15:30)
- biospace.com/
GBT
|
$68.49
0.02%
-0.02%
|
Health Technology
|
128.46%
|
O:
-12.83%
H:
0.0%
C:
0.0%
gbt0216
health
disease
positive results
phase 1
positive
results
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
Published:
2021-12-13
(Crawled : 15:00)
- biospace.com/
FATE
|
News
|
$4.38
-3.52%
530K
|
Health Technology
|
-90.76%
|
O:
-0.1%
H:
0.0%
C:
0.0%
ft516
fda
granted
therapeutics
phase 1
positive
therapy
t-cell
designation
Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting
Published:
2021-12-13
(Crawled : 15:00)
- biospace.com/
RCKT
4
|
$23.67
91K
|
Health Technology
|
4.23%
|
O:
1.14%
H:
0.0%
C:
0.0%
treatment
ema
als
anemia
gene therapies
positive
gene therapy
Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting
Published:
2021-12-13
(Crawled : 14:30)
- biospace.com/
KYMR
|
$35.3
-1.15%
67K
|
Health Technology
|
-32.69%
|
O:
-0.57%
H:
0.0%
C:
0.0%
ema
therapeutics
preclinical
positive
pre-clinical
Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial
Published:
2021-12-13
(Crawled : 14:00)
- biospace.com/
GLTO
|
$0.7006
24K
|
Health Technology
|
-73.28%
|
O:
-5.73%
H:
0.0%
C:
0.0%
gb1211
galectin-3
cirrhosis
phase 1b
liver
trial
liver cirrhosis
phase 1
positive
results
phase 2b
Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab
Published:
2021-12-13
(Crawled : 13:30)
- biospace.com/
EQ
|
$1.72
15K
|
Health Technology
|
-63.87%
|
O:
-0.21%
H:
0.95%
C:
-2.11%
disease
positive
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
Published:
2021-12-13
(Crawled : 12:30)
- biospace.com/
BLU
|
$14.74
0.03%
0
|
Health Technology
|
153.26%
|
O:
35.91%
H:
0.0%
C:
0.0%
blu-5937
treatment
health
phase 2
phase 2b
trial
topline results
positive
results
topline
chronic cough
4D pharma announces positive topline results from Part A of Phase I/II trial of MRx-4DP0004 for the treatment of asthma
Published:
2021-12-13
(Crawled : 08:00)
- 4dpharmaplc.com
LBPS
|
$1.65
-0.61%
|
Manufacturing
|
-74.22%
|
O:
-4.06%
H:
0.0%
C:
0.0%
dp0004
treatment
trial
topline results
positive
results
topline
Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session
Published:
2021-12-13
(Crawled : 08:00)
- prnewswire.com
SNYNF
|
News
|
$94.25
480
|
Health Technology
|
-2.92%
|
O:
3.01%
H:
0.28%
C:
-2.39%
SNY
|
News
|
$46.82
-1.82%
510K
|
Health Technology
|
-3.58%
|
O:
-0.42%
H:
0.0%
C:
0.0%
REGN
|
News
|
$911.73
0.49%
97K
|
Health Technology
|
37.13%
|
O:
-1.54%
H:
0.0%
C:
0.0%
dupixent
atopic dermatitis
dermatitis
positive
children
phase 3
Gainers vs Losers
57%
43%
Top 10 Gainers
CSSE
4
|
$0.3686
142.02%
76M
|
Consumer Services
CZOO
|
$11.685
134.17%
7.6M
|
BOF
|
$2.05
75.21%
78M
|
AMST
|
$3.14
57.0%
59M
|
Technology Services
LICN
|
$0.7885
40.8%
11M
|
TROO
|
$1.51
38.53%
5.6M
|
Manufacturing
MULN
|
News
|
$3.7
35.53%
6.4M
|
Information
WHLM
|
$6.61
30.12%
400K
|
Commercial Services
RILY
|
$27.91
28.5%
8.9M
|
Finance
RBBN
4
|
$3.25
26.46%
1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.